Aspirine werkt preventief ter voorkoming van darmkanker, maar alleen als het jarenlang wordt ingenomen.

14 november 2018: lees ook dit artikel:

https://kanker-actueel.nl/aspirine-ter-voorkoming-van-kanker-of-een-recidief-van-kanker-een-overzicht-van-studies-met-aspirine.html

31 mei 2011: zie ook de nieuwste bevindingen van het WCRF over de relatie tussen leefstijl en voeding en het risico op (darm) kanker. Klik hier voor nieuwste studiegegevens

31 mei 2007: Bron: Lancet. 2007 May 12;369(9573):1603-13.

Wie dagelijks jarenlang aspirine slikt vermindert daarmee het risico op darmkanker. Dit bijkt uit een overzichtsstudie van gerandomiseerde studies gepubliceerd in The Lancet. Het blijkt dat het preventieve effect pas optreedt als er echt jarenlang aspirine geslikt wordt. Of dat nou echt een aanbeveling is durven we niet te zeggen. Persoonlijk zou ik daar niets voor voelen en me gewoon houden aan gezond eten maar wellicht dat anderen dit wel een goed idee vinden.

Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.

Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial.
Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford OX2 6HE, UK.

BACKGROUND: Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up. However, the delay from the early development of adenoma to presentation with cancer is at least 10 years. We aimed to assess the longer-term effect of aspirin on the incidence of cancers.

METHODS: We studied the effect of aspirin in two large randomised trials with reliable post-trial follow-up for more than 20 years: the British Doctors Aspirin Trial (N=5139, two-thirds allocated 500 mg aspirin for 5 years, a third to open control) and UK-TIA Aspirin Trial (N=2449, two-thirds allocated 300 mg or 1200 mg aspirin for 1-7 years, a third placebo control). We also did a systematic review of all relevant observational studies to establish whether associations were consistent with the results of the randomised trials and, if so, what could be concluded about the likely effects of dose and regularity of aspirin use, other non-steroidal anti-inflammatory drugs (NSAID), and the effect of patient characteristics.

RESULTS: In the randomised trials, allocation to aspirin reduced the incidence of colorectal cancer (pooled HR 0.74, 95% CI 0.56-0.97, p=0.02 overall; 0.63, 0.47-0.85, p=0.002 if allocated aspirin for 5 years or more). However, this effect was only seen after a latency of 10 years (years 0-9: 0.92, 0.56-1.49, p=0.73; years 10-19: 0.60, 0.42-0.87, p=0.007), was dependent on duration of scheduled trial treatment and compliance, and was greatest 10-14 years after randomisation in patients who had had scheduled trial treatment of 5 years or more (0.37, 0.20-0.70, p=0.002; 0.26, 0.12-0.56, p=0.0002, if compliant). No significant effect on incidence of non-colorectal cancers was recorded (1.01, 0.88-1.16, p=0.87). In 19 case-control studies (20 815 cases) and 11 cohort studies (1 136 110 individuals), regular use of aspirin or NSAID was consistently associated with a reduced risk of colorectal cancer, especially after use for 10 years or more, with no difference between aspirin and other NSAIDs, or in relation to age, sex, race, or family history, site or aggressiveness of cancer, or any reduction in apparent effect with use for 20 years or more. However, a consistent association was only seen with use of 300 mg or more of aspirin a day, with diminished and inconsistent results for lower or less frequent doses.

INTERPRETATION: Use of 300 mg or more of aspirin a day for about 5 years is effective in primary prevention of colorectal cancer in randomised controlled trials, with a latency of about 10 years, which is consistent with findings from observational studies. Long-term follow-up is required from other randomised trials to establish the effects of lower or less frequent doses of aspirin.
,br> PMID: 17499602 [PubMed - in process]

Related Links
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. [JAMA. 2005] PMID: 16118381
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. [Cochrane Database Syst Rev. 2003] PMID: 12535415
Epidemiology of non-steroidal anti-inflammatory drugs and cancer. [Prog Exp Tumor Res. 2003] PMID: 12795046
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. [Important Adv Oncol. 1996] PMID: 8791132
Population-based interventions for reducing sexually transmitted infections, including HIV infection. [Cochrane Database Syst Rev. 2004] PMID: 15106156